logo-loader

Initiation Reports

Health

Tiziana Life Sciences: Transformational potential

Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only...

3 weeks, 3 days ago
Energy

TomCo Energy: Oil sands project moving forward

TomCo (LON:TOM) is an oil & gas exploration and production company which, operates in the...

on 9/7/20
Health

Revive Therapeutics: Initiation report

Revive Therapeutics (CSE:RVV, OTCQB:RVVTF) is a speciality life sciences company focussed on...

on 30/6/20
Health

Eco Equity - Growing ambition

Eco Equity has established a unique position within the fast-growing market for legal cannabis....

on 12/6/20

Updates

Finance

Primary Health Properties: Steady progress, encouraging prospects

Primary Health Properties (LON:PHP) recently announced interim results for the period to June...

1 week, 4 days ago
Tech

Location Sciences: Reassuring trading update

Location Sciences (LON:LSAI), the world leader in location verification for mobile advertising,...

2 weeks ago
Health

MaxCyte: Firing on all cylinders

MXCT made outstanding progress in H1 20 across the business and is set to report revenue growth...

3 weeks, 5 days ago
Health

MaxCyte: A win in gene silencing with APEIRON Biologics

MaxCyte’s new clinical and commercial licence agreement with Apeiron Biologics allows the...

on 8/7/20

Analyst interviews

Tiziana Life Sciences PLC's clinical plan is shaping up says analyst Emma Ulker

Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number...

4 days, 20 hours ago